JohnTSeykoraMD

Dermatopathology

Associate Professor, Dermatology, Perelman School of Medicine

Dr. Seykora is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
421 Curie Blvd
# 1011
Philadelphia, PA 19104
Phone+1 215-662-2597

Fax+1 215-349-8339

University of Pennsylvania Health SystemFellowship, Dermatopathology, 1997 - 1999
University of Pennsylvania Health SystemResidency, Pathology-Anatomic and Clinical, 1993 - 1997
Weill Cornell MedicineClass of 1993

PubMed

LNS8801: An enantiomerically pure agonist of the G protein-coupled estrogen receptor suitable for clinical development.
Christopher A Natale, Sophia Mercado, Richard Zhuang, Cristina Aguirre-Portolés, Israel Olayide
Cancer Research Communications. 2025-03-11
Penn Academy for Skin Health (PASH): An Experiential Pipeline Program in Skin Biology and Dermatology for High-School Students.
Elizabeth A Grice, Donna Brennan-Crispi, Natalia Rodriguez, David J Margolis, John T Seykora
The Journal of Investigative Dermatology. 2025-03-01
Acetyl-CoA synthesis in the skin is a key determinant of systemic lipid homeostasis.
Phuong T T Nguyen, Mia Shiue, Nina Kuprasertkul, Pedro Costa-Pinheiro, Luke T Izzo
Cell Reports. 2025-02-25

Lectures

Structure and Function of the Skin: Pigment, Appendages, Damage & Repair
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/2/2019

Risk Factors for Positive or Equivocal Margins After Wide Local Excision of 1345 Cutaneous MelanomasJuly 23rd, 2020
Study Reveals Possible Solution to Elevated Cancer Risk from Important Anti-Infection DrugNovember 5th, 2019
Safety and Biopsy Outcomes of a Topical Treatment (SM04554) for Male Androgenetic Alopecia (AGA): Results from a Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled TrialJune 1st, 2017